Nuvation Bio Inc. (NUVB) is a publicly traded Healthcare sector company. As of August 21, 2026, NUVB trades at $6.94 with a market cap of $2.55B and a P/E ratio of -16.13. NUVB moved +1.46% today. Year to date, NUVB is -19.23%; over the trailing twelve months it is +152.92%. Its 52-week range spans $1.54 to $9.75. Analyst consensus is strong buy with an average price target of $15.17. Rallies surfaces NUVB's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Rallies tracks hedge fund and 13F ownership for NUVB, including fund holders, share counts, and position changes when data is available.
| Metric | Value |
|---|---|
| Price | $6.94 |
| Market Cap | $2.55B |
| P/E Ratio | -16.13 |
| EPS | $-0.43 |
| Dividend Yield | 0.00% |
| 52-Week High | $9.75 |
| 52-Week Low | $1.54 |
| Volume | 4.82M |
| Avg Volume | 0 |
| Revenue (TTM) | $169.90M |
| Net Income | $-149.83M |
| Gross Margin | 0.00% |
7 analysts cover NUVB: 0 strong buy, 7 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $15.17.